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Despite the availability of renal replacement therapy, acute
kidney injury (AKI) is associated with high mortality and
morbidity. In humans, it is difficult to determine whether AKI
is a cause or consequence of excess morbidity. In animal
models, however, it is increasingly clear that AKI induces
distant organ dysfunction. Identified pathways include
inflammatory cascades, apoptosis, the induction of remote
oxidative stress, and differential molecular expression.
Specifically, growing evidence implicates renal injury as an
instigator and multiplier of pulmonary, cardiac, hepatic,
and neurologic dysfunction. Accurate identification of these
pathways will be critical in developing targeted therapies
to improve outcomes in AKI. The purpose of this review is
to summarize both clinical and preclinical studies of AKI
and its role in distant organ injury.
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Acute kidney injury (AKI) is common, increasing in
incidence, and associated with excess morbidity and
mortality in the critically ill patient.1–3 Despite widespread
availability of renal replacement therapy, a hospitalized
patient who develops AKI faces a mortality risk as high as
40–60%.2,4,5 Much of this mortality risk is thought to stem
from extrarenal complications or the distant organ effects
of AKI.
The mechanisms by which AKI increases the risk of
adverse outcomes are incompletely understood. In humans,
determining causality is difficult: does AKI itself cause excess
morbidity and mortality, or is it simply a by-product of the
underlying severity of illness? Thus, animal models are vital
in order to clarify physiological mechanisms and test new
therapeutics. In these animal models, the causal distinction
is clearer: injuring (or removing) the kidneys results in
deleterious systemic effects and distant organ dysfunction.
Recent experimental models have elucidated some potential
mechanisms of injury, including dysfunctional inflammatory
cascades, oxidative stress, activation of proapoptotic
pathways, differential molecular expression, and leukocyte
trafficking (Figure 1).
The bilateral renal ischemia–reperfusion injury (IRI)
model, which causes both decreased renal function and
ischemic organ injury in experimental animals, has been
most commonly used to study distant organ effects of AKI.
This model is clinically relevant given that a significant
portion of in-hospital AKI is thought to be ischemic in
nature.6 The bilateral nephrectomy (BNx) model, on the
other hand, may represent the isolated impact of absent
renal function. Many experimental studies use both models
to compare the effects of kidney IRI and lack of kidney
function with the lack of kidney function only. Initially
applied to kidney-lung interaction (Table 1), and more
recently used in kidney–heart, kidney–liver, and kidney–brain
studies (Table 2), these experimental models have yielded
important insights in the complex organ cross-talk that
occurs after AKI.
Why is the elucidation of pathways involved in organ
cross-talk in AKI important? Mortality in patients with AKI
is high, and therapy is limited.1,3,7 Increased delivery of renal
replacement therapy does not appear to improve outcomes.8
Identification of the mechanisms by which AKI affects distant
organ function is critical to the development and refinement
of therapies to prevent or attenuate AKI-associated morbidity
and mortality. In this review, we summarize the growing
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Figure 1 |Distant organ consequences of AKI. AKI, acute kidney injury; G-CSF, granulocyte colony-stimulating factor; GFAP, glial fibrillary
acidic protein; GI, gastrointestinal; GSH, glutathione; IL, interleukin; KC, keratinocyte-derived chemokine; TNF, tumor necrosis factor.
Note: Used with permission from Scheel et al. 64
Table 1 | Experimental studies on the pulmonary effects of AKI
AKI model Species Reference Findings
IRI Rat Kramer et al.22 AKI caused increased pulmonary vascular permeability; macrophage inhibition attenuated this response.
IRI and BNx Rat Rabb et al.25 AKI in both models caused downregulation of lung ENaC, Na,K-ATPase, and aquaporin-5; unilateral IRI
did not.
IRI Mouse Deng et al.26 ALI occurred within 4 h after AKI; treatment with an anti-inflammatory cytokine (a-MSH) decreased lung injury.
IRI Mouse Nath et al.24 ALI and mortality after AKI was heightened in the presence of baseline comorbid condition (sickle-cell disease).
IRI, BNx and
sepsis
Rat Kim et al.29 ALI occurred in all AKI models; ALI after BNx had less cellular infiltration and different inflammatory mediator
expression as compared with ALI from sepsis.
IRI and BNx Mouse Zarbock et al.33 Acid-induced ALI was attenuated in the presence of AKI via either model; impaired pulmonary recruitment of
uremic neutrophils mediated this response.
IRI and BNx Mouse Hoke et al.23 ALI occurred after AKI in both models; serum cytokine profiles after AKI varied by AKI model; IL-10 attenuated
lung injury after bilateral nephrectomy.
IRI and BNx Mouse Hassoun
et al.30
ALI occurred after IRI but not BNx; transcriptional changes in the lung after IRI were distinct from those after
BNx.
IRI Mouse Tracz et al.28 IL-6 levels were significantly elevated after IRI in heme oxygenase-1 (HO-1/) knockout mice (which are
highly sensitive to IRI); IL-6 antibodies decreased their exaggerated renal and mortality response to IRI.
IRI and BNx Mouse Klein et al.27 ALI after AKI by either method was attenuated in IL-6-deficient mice and in wild-type mice treated with
anti-IL-6 antibody.
IRI Mouse Hassoun
et al.31
Lung activation of 66 apoptosis-related genes occurred after AKI; correlated with TUNEL staining and active
caspase-3 activity, indicating pulmonary epithelial apoptosis.
IRI Mouse Awad et al.32 Used flow cytometry to follow in vivo neutrophil trafficking, showed an increase in marginated neutrophils
but not interstitial neutrophils in the lung after kidney ischemia.
Abbreviations: AKI, acute kidney injury; ALI, acute lung injury; BNx, bilateral nephrectomy; ENaC, epithelial sodium channel; IL, interleukin; IRI, ischemia–reperfusion injury;
a-MSH, a-melanocyte-stimulating hormone; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling.
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evidence of the causal and modulatory role of AKI in
dysfunction of the lung, heart, liver, and brain.
KIDNEY–LUNG INTERACTIONS: CLINICAL STUDIES
Respiratory complications are frequently associated with
AKI. In a study of AKI after radiocontrast administration,
78% of patients not previously ventilated developed sub-
sequent respiratory failure.9 Similarly, AKI is a common
occurrence in mechanically ventilated patients. In the first
Acute Respiratory Distress Syndrome (ARDS) Network trial,
24% of patients with ARDS developed AKI within 4 days of
study enrollment.10–12 Mortality is increased in AKI patients
requiring mechanical ventilation,13–15 as well as ventilated
patients developing AKI.12
Clinical studies suggest that the association between AKI
and respiratory failure is not solely due to shared antecedent
comorbidities: AKI itself may increase the risk of severe
extrarenal morbidity.9 In a matched pairs cohort design,
patients developing AKI after radiocontrast administration
were matched to patients who did not develop AKI after a
similar contrast study. Even after adjustment for pre-existing
comorbid conditions, the development of AKI was associated
with a greater than fivefold increase in mortality risk. Patients
with AKI had subsequent hospital courses marked by excess
sepsis, delirium, and respiratory failure.
Inflammatory cytokines are potential mediators of the
distant effects of AKI. Increases in inflammatory cytokines
interleukin (IL)-6 and/or IL-8 preceded rises in serum
creatinine in cohorts of patients with sepsis,16 acute lung
injury,12 after cardiopulmonary bypass,17,18 and in kidney
transplant recipients with transplant-related ischemic
injury.19 High levels of IL-6 were associated with prolonged
weaning times from the ventilator17 and mortality in patients
with AKI and acute lung injury.20,21 Furthermore, unique
patterns of cytokines were associated with death and the
development of AKI in patients with acute lung injury,
suggesting that AKI induces a distinct inflammatory
footprint not solely reflective of the underlying severity of
illness.12
KIDNEY–LUNG INTERACTIONS: ANIMAL MODELS
Increased vascular permeability
Building on the observed association between AKI and lung
injury in humans, early work in animal models demonstrated
that primary renal injury could lead to secondary lung
injury.22 In a rat model of bilateral renal IRI, there was
increased lung vascular permeability at 24 and 48 h post
ischemia, quantified by extravasation of labeled albumin
outside the vascular space. Histological examination was
consistent with defects in vascular permeability, with
interstitial edema, occasional areas of alveolar hemorrhage,
and red blood cell sludging.
Subsequent studies using a mouse model of sham surgery,
unilateral IRI, bilateral IRI, and BNx demonstrated abnormal
lung histology in animals undergoing BNx or bilateral renal
IRI, but not unilateral IRI or sham surgery.23 Furthermore,
all experimental animals lost weight, suggesting that the
pathological changes were not solely secondary to total body
fluid accumulation.22,23 In addition, AKI-induced lung injury
was much worse in the presence of a comorbidity, sickle-cell
disease, supporting the concept of the modulatory effect of
AKI on pre-existing conditions.9,24
Dysregulated channels
Postulating that the observed pulmonary edema after AKI
was secondary to poor alveolar salt and water clearance, lung
tissue was examined for transporters in a similar four-way rat
model.25 There was significantly decreased lung mRNA
expression of epithelial sodium channel and aquaporin-5,
with a concomitant decrease in aquaporin-5 protein. These
results were consistent in models of BNx and bilateral renal
IRI, but not unilateral IRI or sham surgery, providing
evidence that differential protein expression is mediated
by systemic effects of AKI and not just via by-products
of ischemia.
Increased cytokines and chemokines
Animal models support the role of inflammatory cytokines
as systemic mediators of kidney–lung cross-talk. There was
Table 2 | Experimental studies on heart, liver, and brain effects of AKI
Organ Species Reference Findings
Heart Mouse Kelly46 IRI but not BNx led to cardiac apoptosis and increased cardiac cytokines; blocking TNF-a reduced cardiac
apoptosis.
Heart Mouse Nath et al.24 Compared with wild-type mice, cardiac vascular congestion was significantly worse after IRI in sickle-cell
mice.
Liver Mouse Miyazawa et al.49 Increased hepatic accumulation of neutrophils and intermediate T cells were seen after unilateral IRI.
Liver Mouse Serteser et al.52 Hepatic effects of IRI, including elevated TNF-a, MPO activity, and decreased antioxidant activity, were
seen after only 30min of renal ischemia and 1 h reperfusion.
Liver Rat Golab et al.50 IRI and BNx led to early leukocyte infiltration and congestion in the liver; increased oxidative stress
in the liver and elevated hepatic levels of TNF-a were also seen.
Liver Mouse Park et al.51 IRI and BNx led to acute hepatic dysfunction, peri-portal neutrophil infiltration; blocking TNF-a,
IL-17A, or IL-6 protected against AKI-induced hepatic injury.
Brain Rat Adachi et al.62 Dopamine turnover was reduced in the striatum, mesencephalon, and hypothalamus after IRI.
Brain Mouse Liu et al.63 IRI led to disruption in the blood–brain barrier, increased neuronal pyknosis and microgliosis in the
brain, and functional impairment in locomotor activity.
Abbreviations: AKI, acute kidney injury; BNx, bilateral nephrectomy; IL, interleukin; IRI, ischemia–reperfusion injury; MPO, myeloperoxidase; TNF, tumor necrosis factor.
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significant attenuation of lung injury in a bilateral renal IRI
rat model using CNI-1493, an inhibitor of macrophage
activation (via inhibition of IL-1, tumor necrosis factor
(TNF), and IL-6, but not of anti-inflammatory cytokines
IL-10 and transforming growth factor-b), independent of an
effect on AKI.22 In another study, both renal and lung injury
were decreased by pretreating mice undergoing bilateral IRI
with a-melanocyte-stimulating hormone, which has a broad
array of anti-inflammatory effects.26
The balance of proinflammatory and anti-inflammatory
cytokines may be important in modulating AKI-induced
lung injury. Wild-type mice treated with BNx or bilateral
IRI had increased myeloperoxidase (MPO) activity, kera-
tinocyte-derived chemokine (KC; the murine equivalent of
IL-8, a neutrophil chemokine), and macrophage inflamma-
tory protein-2 (a neutrophil chemoattractant) expression.23,27
Administration of the anti-inflammatory cytokine IL-10
attenuated neutrophil accumulation, with a reduction in
pulmonary MPO and pulmonary macrophage inflammatory
protein-2.23 Reduction in the proinflammatory cytokine IL-6
achieved similar results. IL-6-deficient mice had reduced
MPO activity and KC expression after AKI, as did mice
treated with an IL-6 antibody.27 Conversely, administration
of exogenous IL-6 resulted in increased pulmonary MPO
activity.27
Additional evidence for the importance of IL-6 signaling
pathways was provided in experiments involving heme
oxygenase-1 (HO-1), an enzyme involved in the degradation
of heme.28 The upregulation of HO-1 in ischemic kidney is
thought to be an adaptive response, as knockout HO-1 mice
demonstrate a significantly reduced glomerular filtration rate
after renal ischemia. After bilateral renal IRI, serum, kidney,
lung, and heart IL-6 and IL-6-dependent signaling were
significantly increased in HO-1 knockout mice compared
with wild type. In addition, an IL-6 antibody administered
before ischemia to HO-1 knockout mice significantly
attenuated AKI and decreased mortality.
Distinct inflammatory responses
The inflammatory mechanisms by which secondary lung
injury occurs after renal injury are distinct from those seen in
sepsis-induced lung injury.29 Comparing cytokine induction
in the lungs of rats with sepsis and BNx uncovered different
patterns of inflammatory mediator and heat-shock protein
expression. Although lung injury and pulmonary vascular
alterations were similar in the two models, rats with BNx-
induced lung injury had significantly less cellular infiltration
and a marked increase in the proinflammatory chemokine
CINC2. Rats with sepsis-induced lung injury, on the other
hand, had evidence of TNF-a induction.
Unique systemic inflammatory patterns have also been
observed with different mechanisms of AKI.23 Comparing
mice undergoing sham surgery, unilateral ischemia, bilateral
ischemia, and BNx, it was found that there were varied
increases in serum cytokines by mechanism of injury. Relative
to sham surgery, ischemic injury produced increases in KC
and granulocyte macrophage colony-stimulating factor,
BNx resulted in increased IL-10 and granulocyte colony-
stimulating factor, and both methods of AKI increased IL-6,
IL-1b, and IL-12. In contrast, unilateral ischemia produced
increases in KC only, presumably via increased production
in the ischemic kidney, thus demonstrating the importance of
normal kidney function in the regulation of cytokines.
Transcriptomic changes
Distinct inflammatory signatures of bilateral IRI and
BNx have also been demonstrated via global gene expression
profiling of the lung transcriptome.30 An analysis of
pulmonary RNA expression revealed overlapping but distinct
patterns of candidate gene upregulation and downregulation
in BNx versus IRI mice. Gene ontology analysis showed
time-dependent activation of both proinflammatory and
proapoptotic processes, with upregulation of immune and
inflammation genes early after AKI and later activation of
ubiquitin- and apoptosis-related genes.
The role of proapoptotic processes in AKI-induced acute
lung injury was supported in work combining genomic-based
models with interventional experiments.31 In mouse models
of bilateral IRI, activation of 66 apoptosis-related genes was
identified through a lung candidate gene discovery approach.
These findings were correlated in functional experiments by
increased terminal deoxynucleotidyl transferase-mediated
dUTP nick end-labeling (TUNEL) and increased caspase-3
activity colocalizing with CD34, indicating increased
endothelial apoptosis. In addition, pretreatment with the
caspase inhibitor Z-VAD-FMK reduced microvascular dis-
tortion in the lung after AKI. Finally, a TNF receptor-1-
dependent pathway was implicated by increased transcription
of the TNF receptor superfamily, and the absence of lung
apoptosis in TNF receptor-1 knockout mice.
Increased leukocyte trafficking
Neutrophil infiltration in the lung has been demonstrated in
both BNx and bilateral IRI models of AKI.26,27,29 Unlike the
kidney, however, in which the sequential recruitment of
neutrophils from vasculature to interstitium can be blocked
by an adenosine 2A receptor agonist, only marginated
neutrophils increased in the lung after AKI.32
Altered response to lung injury
Kidney injury may elicit compensatory mechanisms that
attenuate remote organ injury. In a ‘two-hit’ mouse model of
experimental renal injury, followed by hydrochloric acid-
induced lung injury, acute uremia resulted in impaired
pulmonary recruitment of neutrophils following both BNx
and bilateral IRI.33 Furthermore, AKI may exhibit modu-
latory effects that vary with the severity of lung injury. In a
model of ventilator-induced lung injury, mice with AKI had
less lung injury (as quantified by extravasation of Evans Blue
Dye and pulmonary neutrophil infiltration) than sham
animals in high tidal volume-treated strategies, and more
lung injury in low tidal volume-treated strategies.
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Lung injury: effects on the kidney
Kidney–lung cross-talk—the remote influence not only of the
injured kidney on the lung but also of the injured lung on the
kidney—is suggested in clinical studies, but experimental
evidence is conflicting. In a rabbit model of acid-induced
lung injury, TUNEL-positive renal tubular epithelial cells
were seen in animals undergoing high tidal volume
ventilation (an ‘injurious’ strategy), but not in animals
undergoing low tidal volume ventilation (a ‘non-injurious’
strategy).34 Examination by electron micrography demon-
strated increased apoptosis and cytoplasmic bleb formation
in renal tubular epithelial cells of the injurious animals.
Similarly, incubation with plasma from injurious animals
resulted in increased apoptosis in rabbit renal proximal
tubular cells in vitro. Correlation in human studies was
performed by measuring plasma soluble Fas ligand in
patients randomized to a high or low tidal volume strategy
in the ARDS Network clinical trial.10 Patients in the high tidal
volume strategy had significant higher plasma soluble
Fas ligand levels, and changes in serum creatinine were
significantly correlated with changes in soluble Fas ligand.
In contrast, in a canine model of acid-induced lung injury
where blood pressure and fluids could be optimally managed,
there was no change in renal parameters—including renal
blood flow, urine output, serum creatinine, albuminuria, and
kidney histology when compared with sham-operated
animals.35
KIDNEY–HEART INTERACTIONS: CLINICAL STUDIES
Cardiorenal syndromes type 1 and 3, where acute dysfunc-
tion in the heart induces decreased kidney function and vice
versa, respectively, are increasingly recognized but poorly
understood.36 Approximately 20–30% of patients hospi-
talized with congestive heart failure (CHF) will reach
the threshold for Stage 1 AKI defined by the AKI Network,37
and even small amounts of renal injury are associated with
increased mortality in these patients.38 Among patients
with established AKI, ‘cardiac failure’ has been reported as
a common cause of death.39
Acute cardiac decompensation is thought to affect the
kidney via hemodynamic mechanisms, as well as humoral
and immune-mediated pathways.36 Less established is the
mechanism of type 3 cardiorenal syndrome, where AKI
causes an acute cardiac disorder, such as CHF or arrhythmias.
AKI-induced salt and water retention likely increases preload;
however, it is also speculated that AKI induces endothelial
cell activation, cytokine secretion, and proapoptotic cascades,
resulting in myocardial damage via neutrophil infiltration
and myocyte apoptosis and necrosis.40
Increased production and impaired clearance of inflam-
matory cytokines may adversely affect myocardial function
and viability. Elevated levels of TNF and IL-6 are associated
with worsening New York Heart Association functional
status,41 mortality in CHF,42 and the development of
CHF.43 Increases in modulators of apoptotic pathway are
correlated with the severity of CHF.44,45
KIDNEY–HEART INTERACTIONS: ANIMAL MODELS
There are limited experimental studies addressing kidney–-
heart interactions. In transgenic sickle mice, bilateral renal
IRI resulted in marked cardiac vascular congestion and
increased serum amyloid P-component (the murine equiva-
lent of c-reactive protein).24 In wild-type mice, renal
ischemia increased cytokine expression in the heart, caused
apoptosis of myocytes, and impaired cardiac function.46 Post
renal ischemia, cardiac levels of TNF-a, IL-1, and intracel-
lular adhesion molecule-1 were elevated. Cardiac neutrophil
infiltration was suggested by increased MPO activity.
Increased apoptosis was detected by TUNEL staining after
bilateral renal IRI but not after BNx. Administration of
TNF-a antibody decreased cardiac TUNEL staining, suggest-
ing TNF-a-mediated apoptosis as a mechanism for AKI-
induced cardiac dysfunction. Echocardiography in mice with
AKI showed evidence of left ventricular dilation, increased
relaxation time, and decreased fractional shortening.
KIDNEY–LIVER INTERACTIONS: CLINICAL STUDIES
Type 1 hepatorenal syndrome, a deadly complication of
end-stage liver disease, is a well-described cause of AKI.47
Here, altered intra-hepatic hemodynamics are thought to
cause decreased glomerular filtration rate in an intrinsically
normal kidney.48 In contrast, there is limited clinical data on
the effect of AKI on liver function. Liver dysfunction
commonly coexists with AKI, particularly in the intensive
care unit setting, and its presence independently increases the
mortality risk.14
KIDNEY–LIVER INTERACTIONS: ANIMAL MODELS
Altered liver enzymes, increased leukocyte influx
Many of the same processes involved in kidney–lung and
kidney–heart interactions have been observed in the liver:
increased neutrophil infiltration, vascular congestion, and
vascular permeability after AKI.49–51 In addition, both
experimental kidney ischemia and BNx led to elevated
aspartate aminotransferase, alanine aminotransferase, lactate
dehydrogenase, and bilirubin levels.50,51
Increased cytokines and apoptosis
Inflammatory and apoptotic pathways are also implicated in
the kidney–liver cross-talk. Following experimental AKI,
hepatic TNF-a, IL-6, IL-17A, intracellular adhesion mole-
cule-1, KC, IL-10, and monocyte chemoattractant protein-1
are increased.50–52 Knockout mice for TNF-a, IL-17A, and
IL-6 displayed reduced hepatic injury after renal ischemia, as
did wild-type mice treated with antibodies to the cytokines.51
The role of apoptosis was suggested by increased activated
caspase-3 staining in hepatocytes after experimental AKI, as
well as increased TUNEL positivity in the peri-portal
region.50,51
Increased oxidative stress and decreased antioxidants
Renal ischemia can induce hepatic oxidative stress, as
evidenced by the decreased levels of superoxide dismutase
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and total glutathione and increases in liver malondialde-
hyde.50,52 In a rat model of bilateral renal IRI, pretreatment
with a reduced form of the antioxidant glutathione resulted
in a significant improvement in liver histology, as well as
reduced malondialdehyde.50
Altered response to hepatic injury
In contrast to experimental studies in kidney-lung interac-
tion,33 the presence of AKI before a ‘second hit’ of ischemic
hepatic injury exacerbated liver injury.51 Mice treated with
BNx, bilateral renal IRI, or unilateral renal IRI all had
significantly increased alanine aminotransferase, as well as
increased necrosis, vascular congestion, and inflammation
on histological staining. In addition, expression of IL-6,
intracellular adhesion molecule-1, and monocyte chemoat-
tractant protein-1 were much higher in mice undergoing
both AKI and hepatic injury than sham animals, animals
with AKI only, and animals with hepatic injury only.51
KIDNEY–BRAIN INTERACTIONS: CLINICAL STUDIES
Neurological complications of AKI include central nervous
system dysfunction with irritability, attention deficits,
hyperreflexia, postural tremor, decreased mental status,
seizures, and death. Although found in patients with
advanced chronic kidney disease, adverse neurological effects
including ‘uremic encephalopathy’ are thought to be more
common and more severe in AKI.53,54 The pathophysiology
of this interaction is poorly understood. The level of azotemia
does not correlate well with neurological impairment.55
In addition, treatment with renal replacement therapy does
not fully ameliorate the symptoms: sluggishness, memory
impairment, and sleep disturbances may persist.53
The reverse process—renal changes secondary to neuro-
logical disease—is less established. AKI is common in
hospitalized patients, including those with primary neuro-
logical disorders; approximately one-quarter of patients
hospitalized for subarachnoid hemorrhage and acute stroke
experienced AKI.56,57 The development of in-hospital AKI is
associated with significantly worse short-term56 and long-
term mortality.57 In addition, kidney inflammation is
increased in allografts from brain-dead donors.58
KIDNEY–BRAIN INTERACTIONS: ANIMAL MODELS
Classical studies of canine acute uremia demonstrated
significant biochemical alterations in the brain, particularly
in calcium concentrations and water handling.59–61 More
recently, the role of neurotransmitters has received attention.
Bilateral renal IRI resulted in decreased dopamine turnover
in the striatum, mesencephalon, and hypothalamus, as well as
decreased motor activity.62 Mice undergoing renal ischemia
demonstrated increased vascular permeability, alterations in
the blood–brain barrier, and increased inflammation, with
elevated levels of the cytokines KC and granulocyte colony-
stimulating factor. Brain histology revealed increased micro-
glial cells (brain macrophages) and pyknotic neuronal cells in
the hippocampus. No increase in apoptosis was observed.
Functionally, mice with AKI had poor locomotor function
that correlated with the time of kidney ischemia.63
CONCLUSION
AKI is a common clinical condition in the critical care
setting. In humans, extrarenal organ dysfunction frequently
coexists with AKI, potentiating the already high rates of
AKI-associated morbidity and mortality. In animal models, a
growing body of evidence suggests that AKI itself causes
distant organ injury. This deleterious interaction arises, at
least in part, from systemic inflammatory changes, activation
of proapoptotic pathways, increases in leukocyte trafficking,
and dysregulated channel expression. Accurate identification
of these pathways is critical in the development and
refinement of therapies for the prevention and attenuation
of AKI-related morbidity.
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